Headquartered in Switzerland with global operations, Space Peptides provides End-to-End pharmaceutical Peptide CRDMO services at Premium Speed & Quality – covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.
Simtra BioPharma Solutions
As the premier, independently owned CDMO with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions delivers advanced cGMP sterile fill and finish to the highest standard in the industry. Our focused approach is backed by technical rigor, collaborative integrations, and a future-forward mindset designed to support our customers strategic objectives. Biotech and pharmaceutical companies partner with Simtra when they need to take their molecule to market, whether launching their innovation globally, improving their formulation, or proactively mitigating risk to help grow their business. Our teams of tenured experts deliver tailored, flexible solutions to help customers consistently fulfill their product goals at the highest quality, so they get in the hands of the patients who need them most.
SEKISUI
BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial focused CDMO with expertise in proteins and downstream purification. Our fermentation process development and production experience helps smooth technical transfer and process scale up. Our core competencies include E.coli and yeast fermentation, plant protein extraction, large scale bioprocessing, protein purification, bulk formulation, lyophilization and analytical testing. Our production site in the UK has been a leader in the manufacturing of high-quality proteins and specialty biochemicals globally to the healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including proteins for biotherapeutics, pharmaceuticals, and diagnostic medical devices. | SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more BioProduction by SEKISUI is a trusted provider of specialized CDMO services, offering biomanufacturing solutions built on decades of experience in microbial fermentation and downstream processing. We support the full development lifecycle—from strain optimization to clinical-scale manufacturing—catering to a wide range of biologics including enzymes, recombinant proteins, antibody fragments, viral vectors, and plasmids. Our microbial expertise spans multiple expression platforms including E. coli, Pichia pastoris, Bacillus, Streptomyces, Streptococcus, fungi, and yeast, enabling highly flexible and efficient process development for biologics. Our advanced UK facility based in Kent is equipped for full spectrum biomanufacturing services and features: Fermentation capacity from 2 L R&D scale up to 5,000 L production Integrated protein expression services for high-yield production Advanced chromatography and purification suites End-to-end antibody production services Lyophilization and bulk formulation GMP-aligned systems under ISO 9001 and ISO 8 cleanroom classifications In-progress GMP plasmid manufacturing and clinical-grade expansion Environmental control and zero-emissions sustainability framework We also provide expert plasmid production for research and therapeutics, with growing capabilities in viral vector manufacturing for cell and gene therapy markets. As established recombinant protein manufacturers, we support custom expression and scale-up for diverse biopharmaceutical programs. In cell and gene therapy, SEKISUI is committed to enhancing the reliability, scalability, and efficiency of cell culture. Ceglu™, our lead technology, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for culturing stem cells (iPSCs, ESCs, MSCs). To accommodate diverse workflows, Ceglu™ is available in two formats: ready‑to‑use pre‑coated culture ware for research workflows, and an automation‑friendly coating solution for cell manufacturing workflows which can be precoated and sterilized onto closed systems or bioreactor consumables for seamless cell production. With a focus on advancing regenerative medicine, SEKISUI partners with service providers, biopharma organizations, bioprocessing innovators and academia to deliver solutions that meet the evolving needs of the industry. Drop by our booth 5621 to ask us about our GMP-readiness, room temperature storage and iPSC.
Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn. | Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at-scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. | Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization offering bioprocess development and cGMP manufacturing of biopharmaceuticals and related consulting activities, including project management and regulatory support. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, USA, and an affiliate dedicated to cell and gene therapies in Stevenage, UK. | Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), offering process development and cGMP manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, USA, and an affiliate dedicated to cell and gene therapies in Stevenage, UK. | Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability. Rentschler Biopharma brings 50-years of biopharmaceutical CDMO experience in the development and cGMP manufacturing of advanced antibodies and complex proteins, monoclonal antibodies, fusion proteins, recombinant enzymes, as well as advanced therapies. We have leveraged our proven experience top serve more than 170 clients worldwide in compliance with international standards (EMA/FDA). At Rentschler Biopharma, “reliability you can trust” is more than a promise – It’s our commitment. We take pride in our contribution to nearly 25% of FDA-approved biopharmaceuticals in 2023. Working collaboratively with our clients, Rentschler Biopharma provides customized solutions with optimized work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes allow manufacturing for both clinical studies and commercial supply. Ongoing monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC) ensures that each project is properly documented in accordance with regulatory requirements. Bioprocess development – Fast and efficient supply for multiple candidate screening – Robust and scalable CHO cell lines for cGMP manufacturing – Efficient cell culture and purification processes for any protein format – Well-established analytical methods – Advanced formulation development cGMP biomanufacturing – Multiple stainless steel bioreactor lines, including a twin system with 2x 3,000 L, flexible single-use bioreactor lines up to 2,000 L – New state-of-the-art production line with 4 x 2,000L single-use bioreactors in Milford, MA, USA – State-of-the-art purification processes – Guaranteed product quality and purity in accordance with cGMP guidelines As a world-class solution provider, with over 50 years of experience, we ensure optimum time-to-clinic and time-to-market by accelerating timelines to create a competitive advantage for our clients. For seamless market approval, we consult and assist clients with regulatory queries, develop optimized strategies, and generate complete documentation for approval of clinical studies and market launch.
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
Phlow
Phlow is a U.S.-based, Certified B Corporation™ leveraging advanced manufacturing processes to re-imagine the domestic production of key starting materials (KSM), active pharmaceutical ingredients (API), and finished drug products that are critical to U.S. healthcare. Focused on impact, Phlow partners with children’s hospitals, private industry, and the U.S. government to increase access to affordable, high-quality life-changing medicines through advanced manufacturing processes that are fully integrated, comprehensive, and better for the environment. Utilizing its advanced R&D labs and best-in-class, automated API cGMP facilities ranging from kilo to metric ton scales, Phlow provides customized contract development and manufacturing services for small molecule APIs to pharmaceutical and biotech companies. Phlow measures its success by its ability to drive down costs and waste, improve quality and yield, and offer a more environmentally friendly approach to manufacturing medicines that lead to healthy and resilient communities. For more, visit www.phlow-usa.com. | Phlow, a B Corporation, helps brilliant minds bring medicines to life through advanced development and manufacturing in America. Focused on innovations in drug substance development, Phlow supports government and private industry customers with scientific expertise, world-class manufacturing, and tech-enabled processes that move the industry toward a new standard as we create the future of how medicines are made. For more information, visit phlow-usa.com.
Phage Consultants
Phage Consultants is a company specializing in bacteriophage problems troubleshooting and prevention. It was founded in 2007 based on many years of experience in this field of its founder. Company, among other phage prevention- and troubleshooting-related activities, provides RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in strict anaerobes. Most probably, we have the greatest experience in this field on the whole global market. | PHAGE CONSULTANTS specializes in prevention and troubleshooting of phage contamination problems in various production and laboratory setups through a variety of services. We offer phage detection and identification services, facility audits and initial assessments, consultations, personnel training, advice on bioprocess optimization and SOP improvement, and new facility development. We also offer fast and reliable routine or as-required testing of incoming bacterial strains and cell banks for the presence of both lytic phages and prophages – a necessary tool in phage prevention. With these services, Phage Consultants can help you avoid phage contaminations and recover quickly from contaminations that have already occurred. | We are a company specializing in phage contamination troubleshooting and prevention with 18 years of experience on the market. We helped to solve over 200 cases of phage contamination in production facilities and research labs. Among the other activities, we provide RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in very unusual hosts like strict anaerobes. Such tests are very important in order to provide smooth production process and to avoid any problems with ready product. We also provide contract research in any field of phage use, which may be also the modification and fine tuning of microbiome. If our activity is anyhow interesting for you, I would be delighted to schedule a meeting with your representative.